TY  -  
T1  - Oncolytic adenovirus drives specific immune response generated by a poly-epitope pDNA vaccine encoding melanoma neoantigens into the tumor site 
SN  -  /  
UR  - http://hdl.handle.net/10138/306973 
T3  -  
A1  - Lopes, Alessandra; Feola, Sara; Ligot, Sophie; Fusciello, Manlio; Vandermeulen, Gaëlle; Préat, Véronique; Cerullo, Vincenzo 
A2  -  
PB  -  
Y1  - 2019 
LA  - eng 
AB  - Background: DNA vaccines against cancer held great promises due to the generation of a specific and long lasting immune response. However, when used as a single therapy, they are not able to drive the generated immune response into the tumor, because of the immunosuppressive microenvironment, thus limiting their use in humans. To enhance DNA vaccine efficacy, we combined a new poly-epitope DNA vaccine encoding melanoma tumor associated antigens and B16F1-specific neoantigens with an oncolytic vi... 
VO  -  
IS  -  
SP  -  
OP  -  
KW  - ACTIVATION; CANCER; Cancer; DNA vaccine; EFFICACY; IDENTIFICATION; INTERLEUKIN-2; Melanoma neoantigens; NATURAL-KILLER-CELLS; NK CELLS; Oncolytic adenovirus; RECEPTOR; RECRUITMENT; THERAPY; Tumor microenvironment; 3122 Cancers 
N1  -   
PP  -  
ER  -